Identification of bactericidal antibody specificities for the development of novel broad-coverage vaccine candidates against Neisseria meningitidis
鉴定杀菌抗体特异性,用于开发针对脑膜炎奈瑟菌的新型广泛覆盖候选疫苗
基本信息
- 批准号:10256250
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-12 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdhesionsAdultAnimal ModelAnimal TestingAnnual ReportsAntibodiesAntibody RepertoireAntibody SpecificityAntigen TargetingAntigensApplications GrantsBaculovirus Expression SystemBinding ProteinsBiological AssayBlood CirculationBlood specimenCellsChildChildhoodCloningCollaborationsCommunitiesComplementComplement ActivationCoupledDataDepositionDevelopmentDiseaseEscherichia coliFemaleFoundationsFutureGenerationsGenesGenetic TranscriptionGoalsGoldGram-Negative BacteriaHealthcareHospitalsHumanImmune SeraImmunityImmunoassayImmunoglobulin GIn VitroIndividualInfectionInfection preventionInvadedLengthLibrariesLondonManufacturer NameMeasurementMeasuresMeningesMeningitisMeningococcal vaccineMicroarray AnalysisMucous MembraneNeisseria meningitidisOpen Reading FramesOperative Surgical ProceduresPatientsPhasePlasmablastPrintingProtein ArrayProteinsProteomeRecombinant ProteinsResearchSamplingSepticemiaSerumSlideSmall Business Innovation Research GrantSpecificitySystemTarget PopulationsTechnologyTherapeutic InterventionTissuesTransgenic MiceTranslationsVaccine AntigenVaccinesValidationantigen antibody bindingantigen bindingbactericidebaseclinical developmentcollegecommercializationcross reactivityhuman monoclonal antibodiesimmunogenicimmunogenicityin silicointerestmalemouse modelnext generationnovelnovel vaccinespediatric patientspreclinical developmentpreventsafety testingsynergismtoolvaccination outcomevaccine candidatevaccine discoveryvaccinology
项目摘要
ABSTRACT
Neisseria meningitidis (Nm) is a Gram-negative bacterium that commonly colonizes the human pharyngeal
mucosa, but can also cause invasive meningococcal disease (IMD), a devastating disease that presents as
septicemia and meningitis. More than 70,000 cases of IMD are reported annually worldwide with case fatality
ratios between 5% and 15%. Bactericidal anti-Nm antibodies may prevent infection and colonization and can be
identified by the serum bactericidal assay (SBA), which is the gold standard in vitro surrogate of protection.
Vaccination that results in protective bactericidal IgG is, therefore, considered a crucial control measure
for IMD. A “Reverse Vaccinology” approach that starts with in silico prediction of vaccine antigens has led to
licensed protein-based vaccines such as the multicomponent 4CMenB (Bexsero®). However, all licensed anti-
Nm vaccines have limited breadth of coverage, leaving vaccinees susceptible to IMD caused by non-vaccine
type strains. There is an urgent need for continued discovery of vaccine candidates that will provide full coverage,
either individually or in synergy with existing vaccines. We hypothesize that the next generation of Reverse
Vaccinology (“RV 2.0”), whereby SBA-active human monoclonal antibodies (hmAbs) are generated from
convalescent IMD patients, will provide the platform for discovery of vaccine antigens against Nm. The team of
Prof. Paul Langford and Dr. Fadil Bidmos of Imperial College London have generated novel broadly protective
bactericidal hmAbs from convalescing patients. The current challenge with RV 2.0 is identifying the cognate
antigens of bactericidal hmAbs. Antigen Discovery, Inc. (ADI) of Irvine, CA has established panproteome
microarray technology for identification of the protein targets of antibodies associated with protective immunity.
A proteome-scale platform for profiling antibody specificity has never before been available to the Nm
research community, and this technology has the power to rapidly advance discovery of vaccine
candidates. This project aims to identify the antigens targeted by bactericidal antibodies. A Neisseria
meningitidis panproteome microarray will be developed for use in an RV 2.0 approach to screen hmAbs and
convalescent sera from pediatric IMD patients characterized as having SBA and other in vitro functional antibody
activity, such as complement activation, opsonophagocytosis and adhesion inhibition. The most promising
antigens will be validated by producing and purifying recombinant proteins, which will be used to develop
Luminex assays for confirmation in orthologous immunoassays. At least 5 vaccine candidate antigens that bind
antibodies that recognize diverse Nm strains, are broadly immunogenic in the target population and are not
currently included in any licensed vaccine will be taken forward for preclinical development in a Phase 2 SBIR
application. This grant application addresses the significant problem of IMD in children and adults by laying the
foundation for a broad-coverage vaccine through identification of the protein targets of bactericidal antibodies.
摘要
脑膜炎奈瑟氏菌(Nm)是一种革兰氏阴性细菌,通常定植于人类咽部
脑膜炎球菌病(IMD)是一种破坏性的疾病,
败血症和脑膜炎。全世界每年报告的IMD病例超过70,000例,并有病例死亡
5%到15%之间。杀菌抗Nm抗体可以预防感染和定殖,并且可以在体内施用。
通过血清杀菌试验(SBA)鉴定,这是体外保护替代物的金标准。
因此,产生保护性杀菌IgG的疫苗接种被认为是一种关键的控制措施
对于IMD。从疫苗抗原的计算机预测开始的“反向疫苗学”方法已经导致
获得许可的基于蛋白质的疫苗,如多组分4CMenB(Bexsero®)。然而,所有持牌反-
Nm疫苗的覆盖范围有限,使接种者容易受到非疫苗引起的IMD的影响。
型菌株。迫切需要继续发现能够提供全面覆盖的候选疫苗,
单独或与现有疫苗协同。我们假设下一代的逆转者
疫苗学(“RV 2.0”),其中SBA活性人单克隆抗体(hmAb)由以下产生:
恢复期IMD患者,将为发现针对Nm的疫苗抗原提供平台。团队
教授伦敦帝国理工学院的保罗·兰福德和法迪尔·比德莫斯博士创造了一种新的广泛保护性的
来自康复患者的杀菌hmAb。RV 2.0目前的挑战是识别同源
杀菌hmAb的抗原。Antigen Discovery,Inc. (ADI)加州尔湾大学的研究人员已经建立了泛蛋白质组
微阵列技术用于鉴定与保护性免疫相关的抗体的蛋白质靶标。
用于分析抗体特异性的蛋白质组规模平台以前从未提供给Nm
这项技术有能力迅速推进疫苗的发现,
候选人该项目旨在鉴定杀菌抗体所针对的抗原。奈瑟氏
将开发脑膜炎泛蛋白质组微阵列,用于RV 2.0方法筛选hmAb,
来自儿科IMD患者的恢复期血清,其特征在于具有SBA和其他体外功能性抗体
活性,如补体激活、调理吞噬和粘附抑制。最有前途的
将通过生产和纯化重组蛋白来验证抗原,这些重组蛋白将用于开发
Luminex检测试剂盒用于正向免疫测定的确认。至少5种疫苗候选抗原,
识别不同Nm菌株的抗体在目标群体中具有广泛的免疫原性,
目前包含在任何许可疫苗中的疫苗将在2期SBIR中进行临床前开发
应用程序.这项拨款申请解决了IMD在儿童和成人中的重大问题,
通过鉴定杀菌抗体的蛋白质靶点,为广泛覆盖的疫苗奠定基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph J Campo其他文献
A Novel Pan-Proteome Array for High-Throughput Profiling of the Humoral Response to Treponema pallidum subsp. pallidum: a Pre-Clinical Study
一种新型泛蛋白质组阵列,用于高通量分析梅毒螺旋体亚种的体液反应。
- DOI:
10.1101/2024.04.20.590429 - 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Joseph J Campo;E. Romeis;Amit Oberai;Jozelyn V. Pablo;Christopher Hung;A. Teng;Adam D. Shandling;Amber Phan;Austin M Haynes;L. Giacani - 通讯作者:
L. Giacani
Machine learning prediction of malaria vaccine efficacy based on antibody profiles
基于抗体谱的疟疾疫苗功效的机器学习预测
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:4.3
- 作者:
Jacqueline Wistuba;Bernhard Reuter;Rolf Fendel;Stephen L Hoffman;Joseph J Campo;P. Felgner;Peter G. Kremsner;B. Mordmüller;Nico Pfeifer - 通讯作者:
Nico Pfeifer
The effect of emPlasmodium falciparum/em exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01subE/sub vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial
恶性疟原虫暴露和母体抗环子孢子蛋白抗体对婴幼儿接种 RTS,S/AS01E 疫苗后免疫应答的影响:一项 3 期随机临床试验的辅助观察性免疫学研究
- DOI:
10.1016/s1473-3099(24)00527-9 - 发表时间:
2025-03-01 - 期刊:
- 影响因子:31.000
- 作者:
Dídac Macià;Joseph J Campo;Chenjerai Jairoce;Maximilian Mpina;Hermann Sorgho;David Dosoo;Selidji Todagbe Agnandji;Kwadwo Asamoah Kusi;Luis M Molinos-Albert;Simon Kariuki;Claudia Daubenberger;Benjamin Mordmüller;Gemma Moncunill;Carlota Dobaño - 通讯作者:
Carlota Dobaño
Age-Associated Weaker Immunity to Coronaviruses is Characteristic of Children that Develop Multisystem Inflammatory Syndrome following SARS-CoV-2 Infection
与年龄相关的冠状病毒免疫力较弱是感染 SARS-CoV-2 后出现多系统炎症综合征的儿童的特征
- DOI:
10.1101/2023.08.28.555120 - 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
David Camerini;Antonio Arrieta;Arlo Z. Randall;Johannes S. Gach;H. Maecker;J. Hoang;K. Imfeld;Stephanie Osborne;Claudia Enriquez;Christopher Hung;J. Edgar;Adam D. Shandling;Vu Huynh;A. Teng;Jozelyn V. Pablo;D. Forthal;Joseph J Campo;Diane Nugent - 通讯作者:
Diane Nugent
Joseph J Campo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph J Campo', 18)}}的其他基金
Identification of bactericidal antibody specificities for the development of novel broad-coverage vaccine candidates against Neisseria meningitidis
鉴定杀菌抗体特异性,用于开发针对脑膜炎奈瑟菌的新型广泛覆盖候选疫苗
- 批准号:
10404598 - 财政年份:2021
- 资助金额:
$ 30万 - 项目类别:
Discovery of Treponema pallidum antigens for development of a sensitive and specific diagnostic test for syphilis
发现梅毒螺旋体抗原,用于开发敏感且特异的梅毒诊断测试
- 批准号:
10078259 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
Discovery of Treponema pallidum antigens for development of a sensitive and specific diagnostic test for syphilis
发现梅毒螺旋体抗原,用于开发敏感且特异的梅毒诊断测试
- 批准号:
9906085 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
Scanning the Cryptosporidium proteome for vaccine antigens
扫描隐孢子虫蛋白质组寻找疫苗抗原
- 批准号:
10011112 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
Identification of protective Lyme disease antigens using live attenuated vaccines
使用减毒活疫苗鉴定保护性莱姆病抗原
- 批准号:
9173245 - 财政年份:2016
- 资助金额:
$ 30万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别: